How much did Janux Therapeutics raise?

Janux Therapeutics raised $125 Million in a Series B round on April 20, 2021.

Where is Janux Therapeutics based and how big is it?

Janux Therapeutics is based in San Diego, California, United States. Fundz records about 80 employees.

Who are the decision-makers at Janux Therapeutics?

Fundz holds 1 contact at Janux Therapeutics, including the Lab manager . Names and contact details are shown to Fundz members.

Janux Therapeutics Closes $125 Million Series B Financing To Advance Next Generation T Cell Engager Immunotherapies Into Clinical Trials

PUBLIC · JANXApr 20, 2021

Amount Raised

$125 Million

Round Type

Series B

San DiegoBiotechnologyTherapeutics

Description

Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company). Janux’s existing investors, OrbiMed, Avalon Ventures, and Bregua, also participated. The proceeds of the financing will help support the advancement of Janux’s pipeline of next generation T cell engager immunotherapies, including a PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr, into initial proof of concept clinical trials.

Quick answer

Janux Therapeutics raised $125 Million in a Series B round, dated April 20, 2021. Janux Therapeutics is based in San Diego, California, United States.

How much did Janux Therapeutics raise?: Janux Therapeutics raised $125 Million in a Series B round on April 20, 2021.
What does Janux Therapeutics do?: Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer.
Where is Janux Therapeutics based and how big is it?: Janux Therapeutics is based in San Diego, California, United States. Fundz records about 80 employees.
Who are the decision-makers at Janux Therapeutics?: Fundz holds 1 contact at Janux Therapeutics, including the Lab manager . Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Janux Therapeutics that raised within 45 days of this round, from Fundz verified event records.

Ajax Therapeutics, Inc. raised $37M on June 1, 2021.
Clene Nanomedicine raised $9.3M on May 26, 2021.
Numab Therapeutics raised an undisclosed amount (Series C) on May 20, 2021.
Immunome Inc. raised an undisclosed amount (Grant) on May 20, 2021.
MAIA Biotechnology raised $8M (Funding Round) on May 19, 2021.
Eikon Therapeutics raised $103M on May 13, 2021.

Who to call at Janux Therapeutics, and when

A new round usually means Janux Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Janux Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Janux Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Janux Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Janux Therapeutics

Location

San Diego, California, United States

About

Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Janux Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

1 contact

Verified contactsNina K., Lab manager hidden hidden hiddenSee plans and pricing

Predictive Intelligence

Strategic

ML-powered predictions for Janux Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means

Timeline to next round

Series B companies typically work for 15-20 months before raising new capital

Growth expectations

Series B companies are expected to scale rapidly and expand market reach

Janux Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.